Evaluation of the American Thoracic Society Criteria for Predicting Multidrug-resistant Bacteria in Critically Ill Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Jianfeng Xie, Southeast University, China
ClinicalTrials.gov Identifier:
NCT01667991
First received: August 12, 2012
Last updated: August 17, 2012
Last verified: August 2012
  Purpose

Appropriate initial antibiotic treatment based on early diagnosis of etiology will improve the outcome of sepsis. The incidence rates of multidrug-resistant (MDR) bacteria, which are different between countries, will affect the accuracy of etiological diagnoses according to the American Thoracic Society (ATS) guidelines. Therefore the investigators determined the accuracy of the ATS criteria in predicting infection or colonization related to MDR bacteria in China.


Condition
Infection

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective

Further study details as provided by Southeast University, China:

Enrollment: 610
Study Start Date: April 2010
Study Completion Date: September 2011
Detailed Description:

All data concerning patient characteristics at ICU admission and during ICU stay were prospectively collected.Screening for MDR bacteria (using nasal swabs, tracheal aspirates from intubated patients and specimens from the infection location) was performed at ICU admission and discharge. Risk factors for infection or colonization with MDR bacteria were recorded, and the accuracy of the ATS criteria in predicting infection or colonization with these bacteria at ICU admission was documented. All of the infected patients were treated by the attending physician, and the choice and adjustment of antibiotic were in accordance with the recommendations of the ATS guidelines.

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Critically ill patients admitted to icu

Criteria

Inclusion Criteria:

  • All patients hospitalized in the ICU were eligible for this study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01667991

Sponsors and Collaborators
Southeast University, China
Investigators
Study Director: Jianfeng Xie, MD Zhongda Hospital
  More Information

No publications provided

Responsible Party: Jianfeng Xie, Department of Critical Care Medicine, Zhong-Da Hospital, School of Medicine Southeast University, Southeast University, China
ClinicalTrials.gov Identifier: NCT01667991     History of Changes
Other Study ID Numbers: MDR in China 123
Study First Received: August 12, 2012
Last Updated: August 17, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Southeast University, China:
Colonization
infection
multidrug-resistant bacteria
guideline

ClinicalTrials.gov processed this record on April 17, 2014